A compound of Formula a tautomer or a stereoisomeric form thereof, wherein R 1 is hydrogen, C 1-4 alkyl or Ar; provided however that R 1 is C 1-4 alkyl or Ar when L is a covalent bond; R 2 is hydrogen, phenyl, cycloC 3-7 alkyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, piperidinyl, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, C 1-4 alkyloxy and NR 7 R 8; Z is methylene or 1,2-ethanediyl, wherein methylene or 1,2-ethanediyl is optionally substituted with one or two C 1-4 alkyl substituents; L is a covalent bond, -(CH 2) m-n -Y-(CH 2) n -, 1,2-cyclopropanediyl, C 1-6 alkanediyl optionally substituted with one or more substituents selected from the group consisting of tetrahydro-2H-pyranyl, phenyl and C 1-4 alkyloxyC 1-4 alkyl, or C 1-6 alkanediyl wherein two geminal hydrogen atoms are replaced by C 2-6 alkanediyl; m represents 3, 4, 5, 6 or 7; n represents 1, 2 or 3; Y is NH; Ar is a ring system selected from the group consisting of phenyl, indolyl, oxazolyl, benzo[b]thienyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 3,4-dihydro-2H-1,5-benzodioxepinyl, pyridyl, indanyl, 1,2,3,4-tetrahydro-l-naphthalenyl, and naphthalenyl; wherein said ring system is optionally substituted with one or more substituents each independently selected from the group consisting of halo, Ar 2, R 0, C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy and cycloC 3-7 alkyl, and C 1-4 alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of halo and cycloC 3-7 alkyl; Ar 2 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C 1-4 alkyl optionally substituted with one or more halo substituents; R 3 is hydrogen, halo or C 1-4 alkyl; R 4 is hydrogen, halo or C 1-4 alkyl; R 5 is hydrogen or C 1-4 alkyl; X is CR 6 or N; R 6 is hydrogen or C 1-4 alkyl; R 7 is hydrogen or C 1-4 alkyl; R 8 is hydrogen or C 1-4 alkyl; R 0 is a ring system selected from the group consisting of piperidinyl, morpholinyl, cycloC 3-7 alkyl, pyrazolyl and pyrrolidinyl; wherein said ring system is optionally substituted with one or more substituents each independently selected from the group consisting of halo or C 1-4 alkyl optionally substituted with one or more halo atoms; or a pharmaceutically acceptable addition salt or a solvate thereof. R 1 is hydrogen, C 1-4 alkyl or Ar; provided however that R 1 is C 1-4 alkyl or Ar when L is a covalent bond; R 2 is hydrogen, phenyl, cycloC 3-7 alkyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, piperidinyl, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, C 1-4 alkyloxy and NR 7 R 8; Z is methylene or 1,2-ethanediyl, wherein methylene or 1,2-ethanediyl is optionally substituted with one or two C 1-4 alkyl substituents; L is a covalent bond, -(CH 2) m-n -Y-(CH 2) n -, 1,2-cyclopropanediyl, C 1-6 alkanediyl optionally substituted with one or more substituents selected from the group consisting of tetrahydro-2H-pyranyl, phenyl and C 1-4 alkyloxyC 1-4 alkyl, or C 1-6 alkanediyl wherein two geminal hydrogen atoms are replaced by C 2-6 alkanediyl; m represents 3, 4, 5, 6 or 7; n represents 1, 2 or 3; Y is NH; Ar is a ring system selected from the group consisting of phenyl, indolyl, oxazolyl, benzo[b]thienyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 3,4-dihydro-2H-1,5-benzodioxepinyl, pyridyl, indanyl, 1,2,3,4-tetrahydro-l-naphthalenyl, and naphthalenyl; wherein said ring system is optionally substituted with one or more substituents each independently selected from the group consisting of halo, Ar 2, R 0, C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy and cycloC 3-7 alkyl, and C 1-4 alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of halo and cycloC 3-7 alkyl; Ar 2 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C 1-4 alkyl optionally substituted with one or more halo substituents; R 3 is hydrogen, halo or C 1-4 alkyl; R 4 is hydrogen, halo or C 1-4 alkyl; R 5 is hydrogen or C 1-4 alkyl; X is CR 6 or N; R 6 is hydrogen or C 1-4 alkyl; R 7 is hydrogen or C 1-4 alkyl; R 8 is hydrogen or C 1-4 alkyl; R 0 is a ring system selected from the group consisting of piperidinyl, morpholinyl, cycloC 3-7 alkyl, pyrazolyl and pyrrolidinyl; wherein said ring system is optionally substituted with one or more substituents each independently selected from the group consisting of halo or C 1-4 alkyl optionally substituted with one or more halo atoms;